Newsletter · · Ashutosh Agarwal

MA 2027 Funding Halved and Medicare Launches a GLP-1 Bridge Program - Managed Care Under Pressure - Week of June 27, 2026

Managed-care podcast briefing for the week of June 20-27, 2026. An MA distribution operator quantified the 2027 funding squeeze (carriers got 'less than half' of last year's +5.06%, average MA MLR 'over 90%'), Medicare's GLP-1 Bridge Program goes live July 1 with the federal government absorbing the cost, and IQVIA reframed GLP-1s as only about one point of total drug-spend growth.

Managed Care Under Pressure

Week of June 27, 2026: MA 2027 Funding Halved and Medicare Launches a GLP-1 Bridge Program

TL;DR

  • Most actionable item: an MA distribution operator quantified the 2027 funding squeeze from the field. Carriers got "less than half" of last year's +5.06%, average MA medical loss ratio is "over 90%," and AEP 2027 is being called a "blood fest" of plan exits and benefit cuts. A direct read on UNH/HUM/CVS/CI MA margins.
  • New GLP-1 wrinkle for Medicare: CMS launches the Medicare GLP-1 Bridge Program on July 1, 2026, paying for weight-loss GLP-1s outside Part D, so the government, not the Part D/MA plans, absorbs that cost, with a hard cliff at end-2027. Separately, IQVIA data reframed GLP-1s as only about one point of total drug-spend growth.
  • The DOJ overhang did not move. UnitedHealth went on the record repositioning as a technology and data company, but with no MLR figure, no guidance reinstatement, and no DOJ update.

What's new

1. The 2027 MA funding cut, quantified from the distribution trenches. On The Seven Figures Or Bust Podcast! - "Episode 242: CMS, Carriers & Chaos … What's Next?" (2026-06-26), MA field operator Andrew Saul (insurance distribution, not a company exec) laid out the math: last year carriers got a +5.06% rate, "and this year they got left less than half of that in funding." He pegged the proposed rate at roughly a flat "0.09%... up to 2.48[%]" and said "the average MLR in a Medicare Advantage plan is over 90% right now across the nation," with plans that "operate on a 1% profit margin... now 4% over where their profit margin was." His call: "AEP 27 is going to be more of a blood fest... the year of the HMO and the D-SNP and C-SNP," with regional PPOs going non-commissionable and benefit cuts deepening. Why it matters: field-level confirmation that the 2027 MA rate (about +2.5%, less than half of 2026's 5.06%) is below trend, and that carriers are responding with the exact margin-defense playbook (PPO exits, benefit cuts, prior-auth tightening) that drives 2027 EPS for UNH, HUM, CVS/Aetna and CI.

2. UnitedHealth on the record, repositioning as "the Apple of healthcare." On Becker's Healthcare Podcast - "Inside UnitedHealth Group's AI and Technology Strategy" (2026-06-23), payer journalist Jakob Emerson relayed on-the-record commentary from a UNH HQ visit with senior executives including the CEOs of UnitedHealthcare and Optum. UnitedHealthcare COO Mike Baker, on the 2024 CEO murder and the backlash: "you paused, a soul search a little bit. And you ask yourself, am I missing something here? Are we really part of the problem and not part of the answer?" Emerson's takeaway: UNH is presenting as "a technology and data company," investing "$3 billion total between this year and next year combined" in AI, with "a thousand AI use cases currently in production," monetizing claims-coding and scheduling software through Optum Insight. Why it matters (operator commentary): narrative management, not numbers. No MLR figure, no guidance reinstatement, and crucially no DOJ update. The DOJ-overhang thread from prior weeks did not advance.

3. Mark Cuban turns the PBM/MLR bear case into a soundbite. On CareTalk - "Why Healthcare Prices Are Like Fight Club w/ Mark Cuban" (2026-06-26), the Cost Plus Drugs founder (industry entrepreneur and pundit) argued the big PBMs "control the formularies for 85% of insured people," use formulary-demotion threats to keep brand net prices about 50% of list, and, most relevant to insurers, that vertically integrated conglomerates "game the ACAs by owning providers... and they charge themselves more so that they can game the medical loss ratios," citing "$160 billion in annual intercompany transfers." On reform: state-level fixes on reimbursement and self-steering are "happening in multiple states," but the federal Hawley-Warren "breakup big medicine bill" is "pretty much dead in the water." Why it matters (pundit, not operator): sharpens the multi-year-political-overhang bear case on UNH/Optum Rx, CVS/Caremark and CI/Express Scripts, while signaling the most dangerous federal break-up risk is, for now, stalled.

4. Medicare GLP-1 Bridge Program goes live July 1, government eats the cost. On NEJM Interviews - "Stacie Dusetzina on the Medicare GLP-1 program" (2026-06-24), the Vanderbilt health-policy economist explained CMS will cover weight-loss GLP-1s "completely outside of the Medicare Part D benefit" starting July 1, 2026, "the government is paying for these drugs separate from the program." The broader Balance demonstration is on hold (Part D plan sponsors declined the voluntary model); Bridge now runs only through end-2027, with no successor and an "unclear" off-ramp. Why it matters: because the cost sits with the federal government, not the plans, this is a modest relief on the GLP-1-cost-explosion fear for MA/Part D sponsors on the weight-loss indication they weren't covering anyway, but it creates a 2027 cliff and could pressure Part B premiums.

5. Drug spend is up double digits, but GLP-1s are only about one point of it. On The Astonishing Healthcare Podcast - "AH110: Inside the 2026 U.S. Medicine Use Trends Report" (2026-06-26), IQVIA's Michael Kleinrock reported US medicine spend hit "$606 billion in 2025... up 10.6%" (after +14.4% in 2024), but "only... a percentage point of the current growth" came from GLP-1s. The other 9.6 points are spread across dozens of mid-life oncology, immunology and neurology products. He flagged the about $670B gross-to-net spread ($1.363T list vs $606B net) and warned that IRA price negotiation, by stripping rebates, removes the cross-subsidy "that keeps premiums from rising." Why it matters: partially de-escalates the GLP-1-will-break-payers narrative, but confirms the underlying specialty-drug trend that keeps pressuring MLRs is broad and double-digit, not a GLP-1 one-off.

The debate

Bull (margins have bottomed, 2027 is the repricing year): The 2027 rate at about +2.5% is below trend, but carriers know it, and the field tape confirms they are repricing hard into AEP 2027 (PPO exits, benefit cuts, prior-auth tightening, a pivot to HMOs/D-SNPs/C-SNPs where risk dollars are richest). The Medicare GLP-1 Bridge moves weight-loss cost onto the federal balance sheet, and IQVIA's data says GLP-1s are only about one point of drug-trend growth. The federal PBM/insurer break-up bill is dead in the water. Discipline plus a known-bad rate equals margin recovery into 2027.

Bear (a structural, multi-year reset): Average MA MLR "over 90%" is not a one-quarter blip; carriers running about 1% margins are now four points underwater. The funding cut is real and below trend, utilization isn't trending down ("not a single thing is trending down"), and the specialty-drug curve is broadly double-digit. Layer on the political overhang (MLR-gaming accusations aimed squarely at vertically integrated names, plus the unresolved DOJ thread at UNH) and you get multiple compression, not just an earnings air-pocket.

Stocks in play

  • UNH - Bull: on-record repositioning as a tech/data platform, $3B AI build, Optum Insight software monetization; about +2.5% 2027 rate is a known headwind to reprice against. Bear: avg MA MLR >90% pressures the core; the Cuban-style MLR-gaming/PBM political narrative targets Optum Rx; the DOJ coding probe did not advance this week and remains an unquantified overhang. Catalyst: Q2'26 print (MLR vs guide, any FY26 EPS reinstatement), DOJ procedural movement, 2027 bid color.
  • CVS - Bull: Aetna leverage to the 2027 reprice; Caremark scale. Bear: Caremark sits inside the federal/state PBM-transparency frame and the MLR-gaming critique; GLP-1 cost optics. Catalyst: Q2'26 Aetna MLR, Caremark GLP-1 economics, any strategic-review update.
  • HUM - Bull: cleanest pure-play MA leverage to a known-bad 2027 rate; benefits most if discipline holds. Bear: highest beta to the >90% MA MLR backdrop and any further rate/benefit erosion. Catalyst: Q2'26 MLR, 2027 bid/benefit-design color.
  • CI - Bull: Evernorth growth; MA exit removed funding-cycle drag. Bear: Express Scripts squarely in the PBM-reform and MLR-gaming frame. Catalyst: Q2'26 Evernorth growth, PBM rulemaking calendar.
  • ELV - Bull: Carelon offset; MA reprice. Bear: Medicaid work-requirement attrition plus ACA subsidy cliff souring the risk pool. Catalyst: Q2'26 Medicaid/MA MLR splits.
  • CNC - Bull: exchange margins, maturing Medicaid acuity reset. Bear: most exposed to the ACA enhanced-subsidy cliff and procedural Medicaid disenrollment. Catalyst: Q2'26 HBR by segment.
  • MOH - Bull: disciplined Medicaid underwriting. Bear: most Medicaid-levered to work requirements plus state-directed-payment caps. Catalyst: Q2'26 MCR, RFP wins/losses.

Read-throughs

  • Medicaid / exchange insurers (CNC, MOH, ELV): the coverage-loss thread stayed hot. On Health & Veritas (2026-06-25), the hosts noted a new federal rule tightening Medicaid work-requirement medical exemptions, with states to comply by January 2027, citing Arkansas's 2018 experiment where "18,000 people lost coverage in four months" despite 95% already qualifying. On Tradeoffs (2026-06-25), Stanford's Neale Mahoney sized the ACA cliff: "5.8 million people could drop Obamacare plans" as enhanced subsidies lapse. Read-through: deteriorating acuity mix and membership attrition into 2027 for the Medicaid/exchange-heavy names.
  • PBMs / Optum-style arms: the Cuban critique plus Relentless Health Value EP517 (2026-06-24) (where Stacey Richter argued PBMs place drugs behind prior-auth to maximize rebates, not for clinical reasons) and The Liquid Lunch Project (2026-06-24) keep the PBM-transparency narrative alive. Federal break-up risk stalled; state-level reimbursement/steering rules advancing.
  • Providers / hospitals (other side of utilization): Achieving Health - "Washington Watch" (2026-06-24) flagged work requirements and more-frequent eligibility checks beginning January 1, 2027, plus provider-tax/SDP changes, the cost-shift mechanism that lands on commercial rates.
  • GLP-1 cost exposure: the Medicare Bridge (July 1) moves weight-loss GLP-1 cost to the federal government; IQVIA frames GLP-1s as only about one point of drug-trend growth. Net: the GLP-1-as-payer-catastrophe story softened modestly this week, even as the broad specialty-drug curve stays double-digit.

What changed vs last week

  • MA 2027 rate, confirmed and quantified from the field. Last week we were still waiting on follow-on commentary to the about +2.5% final rate. This week the distribution channel put numbers on it ("less than half" of 5.06%, avg MA MLR ">90%", AEP 27 "blood fest"), directional confirmation, now with operational consequences attached.
  • GLP-1 angle moved from PBM formulary to Medicare. Last week's story was CVS Caremark reversing its Zepbound exclusion under ERISA pressure. This week the lens shifted to Medicare's Bridge Program (government-funded, July 1) and IQVIA's "only about one point of growth" reframe, a partial de-escalation of payer GLP-1 fear.
  • UNH, operator color, but the DOJ thread did NOT advance. Last week was an AI-pundit "binary/DOJ" reframe. This week we got genuine on-record operator commentary (COO Mike Baker, $3B AI, Optum Insight), but no DOJ movement, no guidance, no MLR. The overhang is unchanged.